These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22215356)

  • 21. The effects of cycled inhaled aztreonam on the cystic fibrosis (CF) lung microbiome.
    Heirali AA; Acosta N; Storey DG; Workentine ML; Somayaji R; Laforest-Lapointe I; Leung W; Quon BS; Berthiaume Y; Rabin HR; Waddell BJ; Rossi L; Surette MG; Parkins MD
    J Cyst Fibros; 2019 Nov; 18(6):829-837. PubMed ID: 30857926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.
    Plant BJ; Downey DG; Eustace JA; Gunaratnam C; Haworth CS; Jones AM; McKone EF; Peckham DG; Ketchell RI; Bilton D
    J Cyst Fibros; 2017 Nov; 16(6):695-701. PubMed ID: 28392014
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
    Dasenbrook EC; Konstan MW; VanDevanter DR
    J Cyst Fibros; 2015 May; 14(3):370-5. PubMed ID: 25496726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
    Frost F; Young GR; Wright L; Miah N; Smith DL; Winstanley C; Walshaw MJ; Fothergill JL; Nazareth D
    J Cyst Fibros; 2021 Nov; 20(6):994-1002. PubMed ID: 33358119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):967-73. PubMed ID: 22029514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
    J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic Analysis Identifies Novel Pseudomonas aeruginosa Resistance Genes under Selection during Inhaled Aztreonam Therapy
    McLean K; Lee D; Holmes EA; Penewit K; Waalkes A; Ren M; Lee SA; Gasper J; Manoil C; Salipante SJ
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New Inhaled Antimicrobial Formulations for Use in the Cystic Fibrosis Patient Population.
    Campbell CT; McCaleb R; Manasco KB
    Ann Pharmacother; 2016 Feb; 50(2):133-40. PubMed ID: 26692274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhaled antibiotics.
    Tiddens H
    Pediatr Pulmonol Suppl; 2004; 26():92-4. PubMed ID: 15029611
    [No Abstract]   [Full Text] [Related]  

  • 31.
    Keating CL; Zuckerman JB; Singh PK; McKevitt M; Gurtovaya O; Bresnik M; Marshall BC; Saiman L
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis.
    Dhand R
    J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):121-138. PubMed ID: 29077527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis.
    Gibson RL; Retsch-Bogart GZ; Oermann C; Milla C; Pilewski J; Daines C; Ahrens R; Leon K; Cohen M; McNamara S; Callahan TL; Markus R; Burns JL
    Pediatr Pulmonol; 2006 Jul; 41(7):656-65. PubMed ID: 16703579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?
    Bos AC; van Holsbeke C; de Backer JW; van Westreenen M; Janssens HM; Vos WG; Tiddens HA
    PLoS One; 2015; 10(3):e0118454. PubMed ID: 25734630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
    Ballmann M; Smyth A; Geller DE
    Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ; Higashi K; Jansen JP; Capkun-Niggli G; Balp MM; Doering G; Tiddens HA; Angyalosi G
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis.
    Moore JE; Mastoridis P
    J Clin Pharm Ther; 2017 Jun; 42(3):259-267. PubMed ID: 28374433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.